3641-18-7

Upstream product

• 66217-79-6 7-chloro-2,2-dimethyl-pyrano[4,3-d][1,3]dioxine-4,5-dione 
• 62-53-3 aniline 

Downstream Products

• 55267-57-7 3-oxo-N-phenyl-glutaramic acid 
• 854849-07-3 (2,2-dimethyl-6-oxo-5-phenylcarbamoyl-6H-[1,3]dioxin-4-yl)-acetic acid anilide 
• 3643-87-6 2,2-dimethyl-6-phenyl-8H-[1,3]dioxino[5,4-c]pyridine-4,5,7-trione 
• 21298-80-6 (2-hydroxy-[4]quinolyl)-acetic acid 
• 3643-95-6 7-methoxy-2,2-dimethyl-6-phenyl-6H-[1,3]dioxino[5,4-c]pyridine-4,5-dione 
• 3837-26-1 2,2-dimethyl-6-phenyl-8H-[1,3]dioxino[5,4-c]pyridine-4,5,7-trione; morpholine salt 
• 3643-94-5 7-chloro-2,2-dimethyl-6-phenyl-6H-[1,3]dioxino[5,4-c]pyridine-4,5-dione 
• 1202705-91-6 methyl 2,4-dihydroxy-6-oxo-1-phenyl-1,6-dihydro-3-pyridinecarboxylate 

Relevant academic research and scientific papers

PROLYL HYDROXYLASE INHIBITORS

The invention described herein relates to certain pyrimidinedione N-substituted glycine derivatives of formula (I) (formula should be inserted here) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.